Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30,936 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance.
Lin H, Kryczek I, Li S, Green MD, Ali A, Hamasha R, Wei S, Vatan L, Szeliga W, Grove S, Li X, Li J, Wang W, Yan Y, Choi JE, Li G, Bian Y, Xu Y, Zhou J, Yu J, Xia H, Wang W, Alva A, Chinnaiyan AM, Cieslik M, Zou W. Lin H, et al. Cancer Cell. 2021 Apr 12;39(4):480-493.e6. doi: 10.1016/j.ccell.2020.12.023. Epub 2021 Jan 28. Cancer Cell. 2021. PMID: 33513345 Free PMC article.
Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer.
Wang W, Kryczek I, Dostál L, Lin H, Tan L, Zhao L, Lu F, Wei S, Maj T, Peng D, He G, Vatan L, Szeliga W, Kuick R, Kotarski J, Tarkowski R, Dou Y, Rattan R, Munkarah A, Liu JR, Zou W. Wang W, et al. Among authors: lin h. Cell. 2016 May 19;165(5):1092-1105. doi: 10.1016/j.cell.2016.04.009. Epub 2016 Apr 28. Cell. 2016. PMID: 27133165 Free PMC article.
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression.
Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, Szeliga W, Herbst R, Harms PW, Fecher LA, Vats P, Chinnaiyan AM, Lao CD, Lawrence TS, Wicha M, Hamanishi J, Mandai M, Kryczek I, Zou W. Lin H, et al. J Clin Invest. 2018 Apr 2;128(4):1708. doi: 10.1172/JCI120803. Epub 2018 Apr 2. J Clin Invest. 2018. PMID: 29608143 Free PMC article. No abstract available.
Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy.
Li J, Wang W, Zhang Y, Cieślik M, Guo J, Tan M, Green MD, Wang W, Lin H, Li W, Wei S, Zhou J, Li G, Jing X, Vatan L, Zhao L, Bitler B, Zhang R, Cho KR, Dou Y, Kryczek I, Chan TA, Huntsman D, Chinnaiyan AM, Zou W. Li J, et al. Among authors: lin h. J Clin Invest. 2020 May 1;130(5):2712-2726. doi: 10.1172/JCI134402. J Clin Invest. 2020. PMID: 32027624 Free PMC article.
LIMIT is an immunogenic lncRNA in cancer immunity and immunotherapy.
Li G, Kryczek I, Nam J, Li X, Li S, Li J, Wei S, Grove S, Vatan L, Zhou J, Du W, Lin H, Wang T, Subramanian C, Moon JJ, Cieslik M, Cohen M, Zou W. Li G, et al. Among authors: lin h. Nat Cell Biol. 2021 May;23(5):526-537. doi: 10.1038/s41556-021-00672-3. Epub 2021 May 6. Nat Cell Biol. 2021. PMID: 33958760 Free PMC article.
PIKfyve controls dendritic cell function and tumor immunity.
Choi JE, Qiao Y, Kryczek I, Yu J, Gurkan J, Bao Y, Gondal M, Tien JC, Maj T, Yazdani S, Parolia A, Xia H, Zhou J, Wei S, Grove S, Vatan L, Lin H, Li G, Zheng Y, Zhang Y, Cao X, Su F, Wang R, He T, Cieslik M, Green MD, Zou W, Chinnaiyan AM. Choi JE, et al. Among authors: lin h. bioRxiv [Preprint]. 2024 Mar 2:2024.02.28.582543. doi: 10.1101/2024.02.28.582543. bioRxiv. 2024. PMID: 38464258 Free PMC article. Preprint.
PAD4 controls tumor immunity via restraining the MHC class II machinery in macrophages.
Pitter MR, Kryczek I, Zhang H, Nagarsheth N, Xia H, Wu Z, Tian Y, Okla K, Liao P, Wang W, Zhou J, Li G, Lin H, Vatan L, Grove S, Wei S, Li Y, Zou W. Pitter MR, et al. Among authors: lin h. Cell Rep. 2024 Mar 26;43(3):113942. doi: 10.1016/j.celrep.2024.113942. Epub 2024 Mar 13. Cell Rep. 2024. PMID: 38489266 Free PMC article.
30,936 results
You have reached the last available page of results. Please see the User Guide for more information.